AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01881412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Asthma Discharge Instructions
Description: Study MD or nurse provides asthma discharge instructions using a standardized checklist. The topics covered include 1) description of asthma manifestations related to current visit, 2) signs of respiratory distress family should be looking for, 3) instructions to follow up with the child's primary care provider within one week, 4) provision and review of an asthma action plan, 5) provision of a spacer device to be used with inhalers (if family does not already possess), and 6) smoking cessation advice. (if indicated)
Study NCT03841526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glugaon RTU Injection Without Insulin Pump Reduction
Description: 0.15 mg injection without pump reduction
Study NCT01715272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TF037
Study NCT01715272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fleet enema
Study NCT02648243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured intervention at discharge and tailored follow up post discharge
Description: At discharge, pharmacist-delivered personalized intervention would include the following (30-60 minutes session): The pharmacist will perform medication reconciliation and will check the appropriateness and accuracy of discharge medications. - Other potential interventions that could be done by the pharmacist include in addition to medication initiation: dose and/or frequency optimization, changing ACEI with ARB if necessary, changing to another statin if needed, identification of inappropriate or duplicated therapy, etc.~The pharmacist will ensure that a follow-up plan for medication monitoring after discharge is communicated to the patient. The pharmacist will also provide a tailored and thorough counseling to the patient. In addition to the pharmacist delivered intervention at discharge (as described above), the study pharmacist will schedule 2 follow-up sessions (30-60 minutes each session) with the patients at 4 weeks of discharge and at 8 weeks of discharge.
Study NCT00948038 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk
Description: Milk-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate adn 350 mg Ca. Three consumed each day.
Study NCT00948038 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy
Description: Soy-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate and 30 mg Ca. Three consumed each day for 28 days,
Study NCT02715050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active or Placebo Phototherapy (MR4)
Study NCT04296916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOP lowering eye drops
Description: 1. Latanoprost 0.005% eye drops will be the first choice. If an IOP reduction of 20% is not achieved within three months, timolol 0.5% will be added as second medication. If an IOP reduction of 20% is then not achieved, alphagan 0.2% or alphagan-P 0.15% will be added. If an IOP reduction of 20% is then not achieved, the individual will be excluded from the study.~2. If necessary, latanoprost will be switched to other prostaglandin eye drops, alphagan (or alphagan-P) will be switched to brinzolamide 1% eye drops.~3. If necessary, latanoprost and timolol will be switched to Xalacom eye drops, timolol and alphagan will be switched to Combigan eye drops, timolol and brinzolamide will be switched to Azarga eye drops.~4. Once daily in the evening for prostaglandin eye drops, and twice daily for other eye drops.
Study NCT04516031 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior Component Separation with Transversus Abdominis Muscle Release
Description: The posterior component separation technique with transversus abdominis muscle release was done as prescribed in Novitsky et al in 2012.
Study NCT04516031 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mesh-only repair
Description: The prosthetic mesh only repair was done as described by Wantz in 1991.
Study NCT01712503 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Phacoemulsfication cataract surgery and intra-ocular lens implant
Study NCT01712503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phacoemulsfication cataract surgery and intra-ocular lens implant
Study NCT02695576 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Fusion Surgery
Description: Interbody fusion with fixation
Study NCT01881412 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Asthma Discharge Instructions
Description: Study MD or nurse provides asthma discharge instructions using a standardized checklist. The topics covered include 1) description of asthma manifestations related to current visit, 2) signs of respiratory distress family should be looking for, 3) instructions to follow up with the child's primary care provider within one week, 4) provision and review of an asthma action plan, 5) provision of a spacer device to be used with inhalers (if family does not already possess), and 6) smoking cessation advice. (if indicated)
Study NCT02695576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Examination by physiotherapist, motivation of the patient, training in body awareness, physical activity/Qigong, training in water, outdoor pole work, circle training, stabilization training, massage, stretching, lessons and practice in ergonomics.
Study NCT02695576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Examination by physiotherapist, motivation of the patient, training in body awareness, physical activity/Qigong, training in water, outdoor pole work, circle training, stabilization training, massage, stretching, lessons and practice in ergonomics.
Study NCT02695576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: Individual and group lessons performed by psychologists.
Study NCT02695576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Individual and group lessons performed by psychologists.
Study NCT02672618 — intervention group
Intervention type: OTHER
Description: The IRS system is capable of precisely measuring and storing real-time thermal images with a resolution of 320×240 pixels (IRS S6md Shanghai,China). The camera has Focal Plane Array (FPA), Uncooled microbolometer detector, with a thermal sensitivity of 0.05 ℃ at 20℃ to 30℃. The thermal images were captured at a distance of one meter from the various body regions namely face and the images were analyzed by thermal software（version 1.0）.
Study NCT03954249 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erecto Spinae nerve block
Description: The ESPB is a myofascial block alternative to the paravertebral block. It is performed by injecting local anesthetic in the plane between the erector spinae muscle and the spinal transverse process. The ESPB is thought to be safer than the paravertebral block because the transverse process acts as a barrier to the pleura. It has been postulated that local anesthetic spread reaches the paravertebral space and in fact, cadaveric studies have shown dye spreading to involve the ventral and dorsal rami of spinal nerves.
Study NCT03954249 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Analgesia
Description: Patients in the control group will receive standard 100mg pregabalin PO, midazolam 2mg IV, fentanyl 100mcg IV.
Study NCT00294684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Schedule and dosing of corticosteroids following portoenterostomy in infants with biliary atresia are listed below.~Days 1-3: Methylprednisolone, IV-4mg/kg/day, divided BID Days 4-7: Prednisolone, PO-4mg/kg/day, divided BID Week 2: 4 mg/kg/day, divided BID Week 3: 2 mg/kg/day, divided BID Week 4: 2 mg/kg/day, divided BID Week 5: 1 mg/kg/day, once a day Week 6: 1 mg/kg/day, once a day Week 7: 0.8 mg/kg/day, once a day Week 8: 0.6 mg/kg/day, once a day Week 9: 0.4 mg/kg/day, once a day Week 10: 0.2 mg/kg/day, once a day Week 11: 0.1 mg/kg/day, once a day Week 12-13: 0.1 mg/kg/day, every other day Week 14: Stop
Study NCT02188511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A
Description: 90 minutes prior to the bronchoscopy on day 8, the subject will be asked to inhale 10 puffs of a Blu brand e-cigarette (for the nicotine-containing e-cigarette, this is approximately equivalent to \< 1 cigarette). At 30 minutes prior to the bronchoscopy procedure if the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette.
Study NCT02188511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group B
Description: On days 7 and 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
Study NCT02188511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group C
Description: On days 6 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
Study NCT02188511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group D
Description: On days 5 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
Study NCT02188511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group E
Description: On days 4 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).~Exposure to e-cigarettes will be limited to the nicotine equivalent of 1/2 pack of cigarettes to mitigate the risk of addiction to nicotine.
Study NCT03003572 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples will be collected at inclusion to determine anti-Ro/SSA IgE titers (Enzyme Linked ImmunoSorbent Assay ELISA).
Study NCT01798667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8031
Study NCT02943070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rezum System
Description: The Rezūm System treats patients with bothersome urinary symptoms associated with benign prostatic hyperplasia (BPH). The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released, denaturing the cell membranes and causing cell death. The denatured cells are absorbed by the body, which reduces the volume of prostate tissue adjacent to the urethra. The vapor condensation process also causes a rapid collapse of vasculature in the treatment zone, resulting in a bloodless procedure.
Study NCT04347512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine and azithromycin treatment arm.
Description: Patient allocated in this arm receive hydroxychloroquine and azithromycin for 5 days.~For hydroxychloroquine, there is a loading dose of 800 mg per day at D1, followed by 400 mg per day D2-D5.~For azithromycin, there is a loading dose of 500 mg per day at D1, followed by 250 mg per day D2-D5.~Every patient receive as well antibiotic (ceftriaxone 1-2 g per day IV), and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc).
Study NCT04347512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Patient allocated in this arm receive hydroxychloroquine for 5 days. For hydroxychloroquine, there is a loading dose of 800 mg per day at D1, followed by 400 mg per day D2-D5.~Every patient receives as well antibiotic (ceftriaxone 1-2 g per day IV), and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc).
Study NCT04347512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control arm
Description: In this arm, no experimental treatment is prescribed. Patients receive IV antibiotics and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc).
Study NCT04830839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery after Stress Toolkit (ReSeT)
Description: ReSeT involves online modules with parallel videoconferencing sessions. ReSeT integrates two evidence-based treatment methods: cognitive behavioral therapy coping skills (coping CBT) and direct exposure to trauma reminders through a trauma narrative.
Study NCT01817842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile EX cessation support
Description: Mobile EX cessation support is designed to enhance the Washington D.C. Quitline (DCQL) by giving participants the ability track their cessation attempt on a phone-based app and thus create a profile documenting their progress and set-backs over the days or weeks in between QL contacts. Participants receive summary information and graphics that help them understand what is working best for them. Participants also receive 24-hr, momentary access to a set of interactive cessation tools on their phone.
Study NCT01817842 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DC Quitline Support
Description: Participants assigned to standard DC Quitline programming receive 6 proactive QL counseling sessions and optional, free nicotine replacement therapy (NRT).
Study NCT01817842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DC Quitline Support
Description: Participants assigned to standard DC Quitline programming receive 6 proactive QL counseling sessions and optional, free nicotine replacement therapy (NRT).
Study NCT01817842 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Device Control
Description: Mobile phone for use during cessation attempt but with no mEX support components
Study NCT03447405 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dino Egg
Description: DINO EGG speakers, a NICU-safe and developmentally appropriate music player that delivers parent's voice to the bedside of NICU infants. The device passed NCH NICU-safe products committee and has been used in the clinical setting delivering clinical music therapy services (available at bedside to play parents' voice).
Study NCT02044952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine, Tripterygium glycosides
Description: tripterygium glycosides: 2mg/kg/d, oral Mesalazine: 4g/d, oral
Study NCT02740244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active iTBS
Description: Transcranial magnetic stimulation. MagProX100 (MagVenture, Denmark) with a figure-eight coil (MCF-B65)
Study NCT02325518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension
Study NCT02325518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution
Study NCT02740244 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham iTBS
Description: Transcranial magnetic stimulation. MagProX100 (MagVenture, Denmark) with a sham figure-eight coil (MCF-P-B65)
Study NCT04387006 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OMT
Description: OMT techniques were focused on correcting the dysfunctions found during the initial physical examination and included articular and myofascial techniques, balanced ligamentous tension, visceral manipulations and osteopathy in the cranial field
Study NCT04387006 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MP
Description: MP treatment was performed by the same osteopaths who performed OMT and was carried out in the same hospital setting. P treatment consisted of a passive touch without joint mobilization in a protocolled order. The osteopaths were standing next to the bed, they touched lumbar and dorsal spine of the subjects in prone position for 10 minutes, and then in supine position, they touched for 10 minutes the shoulders, the hips, then the neck, the sternum and the chest were touched for 5 minutes each. Another researcher on the placebo protocol specifically trained the osteopaths.
Study NCT03198767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 50 mg tablets. Open-label, bulk, blister-pack.
Study NCT03198767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate 50%
Description: 50% carbohydrate in breakfast meal
Study NCT02325518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subject's habitual PGA monotherapy
Study NCT02325518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subject's habitual PGA monotherapy
Study NCT01004094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: simple goal setting
Description: This group will set goals only
Study NCT01004094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: goal setting plus action intentions
Description: This group will set goals and form action intentions (plans)
Study NCT01004094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: goal setting plus coping intentions
Description: This group will set goals and form coping intentions (plans)
Study NCT01004094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: goal setting plus action intentions plus coping intentions
Description: This group will set goals and form action intentions and coping intentions
Study NCT02249312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS
Study NCT02249312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03198767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate 25%
Description: 25% carbohydrate in breakfast meal
Study NCT03198767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate 8%
Description: 8% carbohydrate in breakfast meal
Study NCT03198767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate 0%
Description: 0% carbohydrate in breakfast meal
Study NCT03198767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyllium
Description: Powder 6 grams
Study NCT03198767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Description: Liquid 1 gram (4 mL equivalent sugar free)
Study NCT01819363 — intervention group
Intervention type: PROCEDURE
Intervention: Pleural elastance
Description: The pleural pressure level will be zero at the time of the insertion site of the drain on the skin. The pleural pressure is set to the value measured at end-expiration. The pleural pressure is measured at baseline, after withdrawal of 10 ml of liquid and thereafter every 400 ml of pleural effusion evacuated to the pressure to be negative, from that moment the measurement will occur every 200 ml of pleural effusion drained to obtain 800 ml of liquid. Patients that are removed less than 800 ml of liquid will be excluded from the protocol. The pleural elastance is then calculated in cm H2O / L and the data placed in a pressure curve by volume.
Study NCT01080924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low frequency ultrasound spectroscopy after broncholysis
Description: Low frequency ultrasound spectroscopy is a novel non-invasive approach to real-time diagnostics of the lungs. Low frequency ultrasound at 10 to 1000 kHz permits monitoring of the air and water contents of the human thorax.
Study NCT02039167 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Left atrial appendage occlusion
Description: Percutaneous left atrial appendage closure using the WATCHMAN device.
Study NCT03391830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin-Ascorbic acid
Description: atorvastatin (80-mg loading dose given a mean 24 hours before procedure with another 40-mg dose approximately 2 hours before the procedure and for 3 days) plus ascorbic acid 500mg
Study NCT03391830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01798667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of DA-8031, undistinguishable
Study NCT03351699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4250
Description: MK-4250 tablets for oral administration
Study NCT02697201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid
Description: 0.55 ml/kg/h
Study NCT02697201 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intralipid
Description: 0.55 ml/kg/h